Vince has over 25 years of experience in the biopharmaceutical industry, including research leadership roles for two marketed drugs. He served as Vice President of Pharmacology at Mavupharma until its acquisition by AbbVie. Before this, he was Senior Director of Research at Omeros Corporation, where in addition to his work on the marketed ophthalmic agent Omidria® he led early stage research and development efforts resulting in the clinical entry of two novel small molecule drugs. Prior to this, he directed research on the PDE5 inhibitor tadalafil (Cialis®, Adcirca®), which is marketed for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension.
Vince earned his BS in biochemistry from Cornell University and his PhD in pharmacology from the University of Virginia.